Models of mild cognitive deficits in risk assessment in early psychosis
- PMID: 38433595
- DOI: 10.1017/S0033291724000382
Models of mild cognitive deficits in risk assessment in early psychosis
Abstract
Background: Mild cognitive deficits (MCD) emerge before the first episode of psychosis (FEP) and persist in the clinical high-risk (CHR) stage. This study aims to refine risk prediction by developing MCD models optimized for specific early psychosis stages and target populations.
Methods: A comprehensive neuropsychological battery assessed 1059 individuals with FEP, 794 CHR, and 774 matched healthy controls (HCs). CHR subjects, followed up for 2 years, were categorized into converters (CHR-C) and non-converters (CHR-NC). The MATRICS Consensus Cognitive Battery standardized neurocognitive tests were employed.
Results: Both the CHR and FEP groups exhibited significantly poorer performance compared to the HC group across all neurocognitive tests (all p < 0.001). The CHR-C group demonstrated poorer performance compared to the CHR-NC group on three sub-tests: visuospatial memory (p < 0.001), mazes (p = 0.005), and symbol coding (p = 0.023) tests. Upon adjusting for sex and age, the performance of the MCD model was excellent in differentiating FEP from HC, as evidenced by an Area Under the Receiver Operating Characteristic Curve (AUC) of 0.895 (p < 0.001). However, when applied in the CHR group for predicting CHR-C (AUC = 0.581, p = 0.008), the performance was not satisfactory. To optimize the efficiency of psychotic risk assessment, three distinct MCD models were developed to distinguish FEP from HC, predict CHR-C from CHR-NC, and identify CHR from HC, achieving accuracies of 89.3%, 65.6%, and 80.2%, respectively.
Conclusions: The MCD exhibits variations in domains, patterns, and weights across different stages of early psychosis and diverse target populations. Emphasizing precise risk assessment, our findings highlight the importance of tailored MCD models for different stages and risk levels.
Keywords: cognition; prediction; schizophrenia; transition; ultra-high risk.
Similar articles
-
Neurocognitive resilience as a predictor of psychosis onset and functional outcomes in individuals at high risk.BMC Med. 2025 Apr 24;23(1):240. doi: 10.1186/s12916-025-04059-1. BMC Med. 2025. PMID: 40275324 Free PMC article.
-
Neurocognitive Assessments Are More Important Among Adolescents Than Adults for Predicting Psychosis in Clinical High Risk.Biol Psychiatry Cogn Neurosci Neuroimaging. 2022 Jan;7(1):56-65. doi: 10.1016/j.bpsc.2021.06.015. Epub 2021 Jul 16. Biol Psychiatry Cogn Neurosci Neuroimaging. 2022. PMID: 34274517
-
Neuropsychological Test Performance to Enhance Identification of Subjects at Clinical High Risk for Psychosis and to Be Most Promising for Predictive Algorithms for Conversion to Psychosis: A Meta-Analysis.J Clin Psychiatry. 2017 Jan;78(1):e28-e40. doi: 10.4088/JCP.15r10197. J Clin Psychiatry. 2017. PMID: 28129494
-
Neurocognition in clinical high risk young adults who did or did not convert to a first schizophrenic psychosis: a meta-analysis.Schizophr Res. 2013 Sep;149(1-3):48-55. doi: 10.1016/j.schres.2013.06.017. Epub 2013 Jul 5. Schizophr Res. 2013. PMID: 23830855 Review.
-
Neurocognitive dysfunction in subjects at clinical high risk for psychosis: A meta-analysis.J Psychiatr Res. 2018 Aug;103:38-45. doi: 10.1016/j.jpsychires.2018.05.001. Epub 2018 May 5. J Psychiatr Res. 2018. PMID: 29772485
Cited by
-
Gender differences in neurocognitive impairment among first-episode, drug-naïve schizophrenia patients: a cross-sectional study.Front Psychiatry. 2025 Aug 4;16:1642291. doi: 10.3389/fpsyt.2025.1642291. eCollection 2025. Front Psychiatry. 2025. PMID: 40831523 Free PMC article.
-
Neurocognitive resilience as a predictor of psychosis onset and functional outcomes in individuals at high risk.BMC Med. 2025 Apr 24;23(1):240. doi: 10.1186/s12916-025-04059-1. BMC Med. 2025. PMID: 40275324 Free PMC article.
-
Advancements and Future Directions in Prevention Based on Evaluation for Individuals With Clinical High Risk of Psychosis: Insights From the SHARP Study.Schizophr Bull. 2025 Mar 14;51(2):343-351. doi: 10.1093/schbul/sbae066. Schizophr Bull. 2025. PMID: 38741342 Free PMC article. Review.
-
Cognitive impairments in first-episode psychosis patients with attenuated niacin response.Schizophr Res Cogn. 2025 Jan 27;40:100346. doi: 10.1016/j.scog.2025.100346. eCollection 2025 Jun. Schizophr Res Cogn. 2025. PMID: 39925786 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical